Though the core mechanism behind CIP2A inhibitors appears to be through the inhibition of CIP2A transcription rather than its binding to PP2A, the overall effect of increasing PP2A activity in cancer cells is still comparable to the SET inhibitors. The gene discussed is SET; the disease is cancer.